Skip to main content

Day: January 28, 2025

Correction: Verkkokauppa.com Oyj: Shareholders’ Nomination Board’s proposals regarding the composition and remuneration of the Board of Directors of Verkkokauppa.com Oyj

Correction: Verkkokauppa.com Oyj: Shareholders’ Nomination Board’s proposals regarding the composition and remuneration of the Board of Directors of Verkkokauppa.com Oyj Verkkokauppa.com Oyj                 STOCK EXCHANGE RELEASE         28 January 2025 at 15:00 EET There was a wrong year and net sales figure in the stock exchange release. The correct sentence is: Verkkokauppa.com’s revenue in 2023 was EUR 503 million and it employs around 600 sales and retail professionals. The corrected release: Verkkokauppa.com Oyj’s Shareholders’ Nomination Board will propose to the Annual General Meeting, planned to be held on 8 April 2025, that the Board of Directors consists of seven members and that Robin Bade, Henrik Pankakoski, Kati Riikonen, Irmeli Rytkönen, Samuli Seppälä, Enel Sintonen and Arja Talma be re-elected as Board members. Should...

Continue reading

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Following a constructive Nasdaq hearing panel on January 7, 2025, Evaxion has been granted a 180-day extension in relation to the Nasdaq minimum equity requirement Evaxion has currently restored its equity above the minimum requirement through exercise of prefunded warrants and sales through its ATM-facility providing $7.8 million, extending its cash runway until Q4 2025 The conversion of Evaxion’s EIB-loan to equity is still expected to be completed in Q1, 2025, which is expected to boost equity Evaxion continues to see strong progress in ongoing business development discussions which is expected to further support equity going forwardCOPENHAGEN, Denmark, January 28, 2025 – Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has received...

Continue reading

Abercrombie Brings Elevated Shopping to Super Bowl LIX

Abercrombie House retail experience in New Orleans features Super Bowl LIX merchandise and NFL starsAbercrombie HouseSuper Bowl LIX Crew Sweatshirt $90 (XS – XXL), available only at Abercrombie House in New Orleans Feb. 8, 10 a.m. – 6 p.m.Abercrombie HouseSuper Bowl LIX Crew Sweatshirt $90 (XS – XXL), available only at Abercrombie House in New Orleans Feb. 8, 10 a.m. – 6 p.m.Abercrombie HouseSuper Bowl LIX Crew Sweatshirt $90 (XS – XXL), available only at Abercrombie House in New Orleans Feb. 8, 10 a.m. – 6 p.m.NEW ALBANY, Ohio, Jan. 28, 2025 (GLOBE NEWSWIRE) — Abercrombie & Fitch (Abercrombie), a division of Abercrombie & Fitch Co. (NYSE: ANF), announced a one-day retail experience in New Orleans leading up to Super Bowl LIX, following the success of its popular licensed...

Continue reading

QXO Comments on Beacon Roofing Supply’s Adoption of Shareholder-Unfriendly Poison Pill

Reaffirms Commitment to Acquiring Beacon for $124.25 per Share in Cash All-Cash Offer Provides Significant and Immediate Value to Beacon ShareholdersGREENWICH, Conn., Jan. 28, 2025 (GLOBE NEWSWIRE) — QXO, Inc. (NYSE: QXO) today commented on Beacon Roofing Supply, Inc.’s (Nasdaq: BECN) adoption of a shareholder rights plan, which takes immediate effect and is aimed at blocking QXO’s all-cash tender offer to acquire all outstanding shares of Beacon for $124.25 per share. “We launched our all-cash tender offer to ensure that Beacon’s shareholders can take advantage of our compelling offer and get paid quickly. We have committed financing, have no due diligence condition and anticipate a smooth regulatory approval process to close,” said Brad Jacobs, chairman and chief executive officer of QXO. “The only thing stopping shareholders...

Continue reading

Invesco Ltd: Form 8.3 – Loungers PLC; Public dealing disclosure

FORM 8.3 PUBLIC DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1. KEY INFORMATION     (a) Full name of discloser: Invesco Ltd.  (b) Owner or controller of interests and short positions disclosed, if different from 1(a):The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.    (c) Name of offeror/offeree in relation to whose relevant securities this form relates:Use a separate form for each offeror/offeree Loungers PLC  (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:    (e) Date position held/dealing undertaken:For an opening position disclosure, state the latest practicable date prior to the...

Continue reading

DIH Announces Strategic Partnership with Nobis Rehabilitation Partners

NORWELL, Mass. and ALLEN, Texas, Jan. 28, 2025 (GLOBE NEWSWIRE) — DIH Holding US, Inc. (“DIH”)(NASDAQ:DHAI), a global provider of advanced robotic devices used in rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions, today announced its new partnership with Nobis Rehabilitation Partners. This collaboration signifies an important advancement as Nobis plans to integrate Andago®, an overground gait and balance training device, into every one of their newly established hospitals. Based in Allen, Texas, Nobis Rehabilitation Partners was founded in 2018 and has rapidly expanded to develop, open, and manage over 17 inpatient rehabilitation...

Continue reading

NV5 to Host Fourth Quarter and Full Year 2024 Conference Call on Thursday, February 20th at 4:30pm ET

HOLLYWOOD, Fla., Jan. 28, 2025 (GLOBE NEWSWIRE) — NV5 Global, Inc. (the “Company” or “NV5”) (Nasdaq: NVEE), a provider of technology, certification, and consulting solutions, will announce its financial results for the fourth quarter ended December 28, 2024, on Thursday, February 20, 2025, following the close of the markets. The Company will host an earnings conference call at 4:30 p.m. Eastern time the same day. NV5 Executive Chairman, Dickerson Wright, Chief Executive Officer, Ben Heraud, and Chief Financial Officer, Edward Codispoti, will host the call along with operational reports by segment leaders. The call will be concluded with a question and answer session.Date: Thursday, February 20, 2025Time: 4:30 p.m. EasternToll-free dial-in number: +1 (800) 715-9871International dial-in number: +1 (646) 307-1963Conference...

Continue reading

HII is Awarded Task Order for Approximately $296 Million to Support Global Air and Space Operations

MCLEAN, Va., Jan. 28, 2025 (GLOBE NEWSWIRE) — HII (NYSE: HII) announced today that its Mission Technologies division was awarded a task order valued at approximately $296 million to support U.S. Air Forces in Europe-Air Forces in Africa’s (USAFE-AFAFRICA) air and space operations around the globe. Under the five-year Consolidated Mission Support task order, awarded by the Air Force Installation Contracting Center’s 764 Enterprise Sourcing Squadron, HII will provide technical and analytical services to assist USAFE-AFAFRICA in the planning, integration and execution of command and control; integrated air and missile defense; and intelligence, surveillance and reconnaissance (ISR). The task order is a follow-on to work that HII does under the Persistent Multi-Role Operations (PMRO) contract with added scope. “Through our continued...

Continue reading

Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference

WALTHAM, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced management’s fireside chat presentation at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 3:00 p.m. ET. A live webcast and archived replay of the Company’s presentation can be accessed under “Events and Presentations” in the Investor & Media Relations section of the Zenas BioPharma website. About Zenas BioPharma, Inc. Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative immunology-based therapies for patients...

Continue reading

CORRECTION: Webinar – presentation of the unaudited financial results for 2024 and Q4 2024

Correction – the webinar takes place on 30 January (erroneously 30 December in original announcement) On Thursday, 30 January, at 13:00 (EET), Liven AS CEO Andero Laur and CFO Joonas Joost will host a Webinar, in Estonian, to present Liven’s unaudited financial results for 2024 and Q4 2024. The webinar will be held on Google Meet. Pre-registration is not required, but please note that no further reminder will be sent. If you wish to save the event to your calendar, please click on the link. Interested parties are invited to join the Estonian webinar on 30 January at 13:00 (EET) via the link:meet.google.com/fgj-bwgh-koz Questions can be submitted during the webinar or by sending them in advance at least one hour before the webinar by e-mail to: investor@liven.ee. The webinar materials will be published later on the Investors...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.